Back to News & Events

Lab Equipment Matching Funds Grant for SBIR/STTR Recipients

Stony Brook University’s Small Business Development Center (SBDC) is administering a program to provide matching funds for laboratory equipment to successful Small Business Innovation Research (SBIR) grant recipients throughout Nassau and Suffolk Counties.

The Program is funded by an incentive package offered by New York State’s Empire State Development Agency to the Stony Brook University Research Foundation and agreed upon in a contract signed May 2, 2014. These matching grants will reimburse up to 20% of the cost for eligible laboratory equipment purchased by SBIR winning companies up to a maximum of $50,000.

If your Long Island-based company has been awarded a SBIR and/or STTR award after May 2, 2014, which identifies your company as active in the federal grant arena, your company may be eligible for this matching grant.
The current time limit of opportunity to apply to the Stony Brook SBDC is April 30, 2025. If all the funds are not expended by that time, the April 2025 date may be extended. Therefore, future SBIR awards, including those currently applied for, may also be eligible for the matching funds.

If you are interested in this opportunity, please contact 631-632-9084 for an appointment. If you have questions about the matching grant prior to making an appointment, please email martha.stansbury@stonybrook.edu.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => 
					SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					FROM wp_posts 
					WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					
					ORDER BY RAND()
					LIMIT 0, 3
				
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4285
                    [post_author] => 4
                    [post_date] => 2023-09-11 12:13:16
                    [post_date_gmt] => 2023-09-11 16:13:16
                    [post_content] => 

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3022 [post_author] => 3 [post_date] => 2018-08-13 15:51:02 [post_date_gmt] => 2018-08-13 15:51:02 [post_content] => Stony Brook University, iCell Gene Therapeutics and University of Louisville collaborate to offer a new CAR T immunotherapy to treat patients. Stony Brook University, iCell Gene Therapeutics, and the University of Louisville, have received Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. The approach is the first to use chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR). Together, Stony Brook University, the University of Louisville, and iCell Gene Therapeutics expect the first in-human Phase I clinical trial to begin accruing patients before the end of 2018. “We are excited to partner with the University of Louisville and iCell Gene Therapeutics to offer this innovative first-in-human CAR T cell immunotherapy clinical trial for patients who are suffering from these extremely difficult to treat T cell lymphomas and leukemias,” said Huda Salman, MD, Principal Investigator for the IND and an oncologist at Stony Brook University Cancer Center. “CD4CAR T cells may prove to be a promising and novel therapy in this setting.” “The development of this trial using CD4 as a target is the first of what we expect to be many CAR T-based clinical trials available to our patients over time,” said Yusuf Hannun, MD, Director of the Stony Brook University Cancer Center. “The pending trial is an example of the type of bench-to-bedside research that is building up at Stony Brook due to the growing expertise and collaborative research environment we are creating and new opportunities that will emerge upon the opening of our Medical and Research Translation (MART) Building.” William Tse, MD, FACP, Chief of the Blood and Marrow Transplantation at the University of Louisville School of Medicine, is the Co-PI of the CD4CAR clinical trial at University of Louisville site. [post_title] => Client News: First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched [post_excerpt] => CFB Client iCell Gene Therapeutics, Stony Brook University, and the University of Louisville, have received FDA clearance for an Investigational New Drug (IND) for the treatment of relapsed and refractory T-cell leukemia and lymphoma. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => client-news-first-in-human-clinical-trial-targeting-cd4-protein-for-aggressive-t-cell-leukemia-and-lymphoma-to-be-launched [to_ping] => [pinged] => [post_modified] => 2018-08-13 15:51:02 [post_modified_gmt] => 2018-08-13 15:51:02 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3022 [menu_order] => 115 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3055 [post_author] => 3 [post_date] => 2018-09-04 13:33:40 [post_date_gmt] => 2018-09-04 13:33:40 [post_content] => Cold Spring Harbor Laboratory’s Alex Vaughan was awarded the 2018 Alexandria LaunchLabs Seed Capital Prize for the CSHL spinoff company MapNeuro Inc. during the NYC Life Science Innovation Showcase, held in New York City on June 14, 2018. Valued at $100,000, the prize, meant to fund early-stage development companies, includes a scholarship to Alexandria LaunchLabs, a cash award, and an investment from the Alexandria Seed Capital Platform, an innovative funding model catalyzing seed-stage life science investment. MapNeuro Inc. commercializes “molecular connectomics” technology developed in the laboratory of CSHL Professor Anthony Zador. MapNeuro uses this platform to understand brain-wide patterns of neuronal connectivity, and is specifically targeting neurodegenerative diseases such as Parkinson’s Disease and Alzheimer’s Disease. Read the full article here. [post_title] => LIBH Innovator Awarded Alexandria LaunchLabs Seed Capital Prize [post_excerpt] => CSHL spin-out MapNeuro Inc. was awarded the 2018 Alexandria LaunchLabs Seed Capital Prize during the NYC Life Science Innovation Showcase in June 2018. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => libh-innovator-awarded-alexandria-launchlabs-seed-capital-prize [to_ping] => [pinged] => [post_modified] => 2018-09-04 13:46:01 [post_modified_gmt] => 2018-09-04 13:46:01 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3055 [menu_order] => 112 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2054 [post_author] => 3 [post_date] => 2015-11-18 19:51:42 [post_date_gmt] => 2015-11-18 19:51:42 [post_content] => Traverse Biosciences has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,187,406 entitled, "Curcumin Analogues as Zinc Chelators and Their Uses," which the company has exclusively licensed from the Research Foundation for the State University of New York (RF/SUNY). The issued patent includes claims that cover the composition of matter of the company's proprietary library of chemically-modified curcumins, including its lead drug candidate, TRB-N0224. Read more on the Traverse Biosciences website.   [post_title] => Traverse Biosciences Announces Issuance of U.S. Patent [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-announces-issuance-of-u-s-patent [to_ping] => [pinged] => [post_modified] => 2016-03-29 19:53:52 [post_modified_gmt] => 2016-03-29 19:53:52 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2054 [menu_order] => 199 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4285 [post_author] => 4 [post_date] => 2023-09-11 12:13:16 [post_date_gmt] => 2023-09-11 16:13:16 [post_content] =>

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 249 [max_num_pages] => 83 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

“Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing” 10/12/23

More Information

Client News: First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched

More Information

LIBH Innovator Awarded Alexandria LaunchLabs Seed Capital Prize

More Information

Traverse Biosciences Announces Issuance of U.S. Patent

More Information